A new paradigm for treating obesity and diabetes mellitus

Scheen, André; Paquot, Nicolas

doi:10.1038/nrendo.2015.3

Cited by 19 publications

(9 citation statements)

References 14 publications

(18 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Of particular significance, unlike the GIPR/GLP-1R dual agonist, the triagonist increased energy expenditure and endogenous circulating FGF21, which are contributed by the GcgR agonism component within the triagonist. The successful in vivo validation of the GcgR/GLP-1R/GIPR triagonist confirms the previously unappreciated yet unique virtues of GcgR and GIPR agonism for the treatment and prevention of obesity and T2D (Scheen and Paquot, 2015). Triagonism offers a number of potential advantages that distinguishes it from either of the respective co-agonists.…”

Section: Get a Gip: ''Twincretins''supporting

confidence: 53%

Unimolecular Polypharmacy for Treatment of Diabetes and Obesity

et al. 2016

View full text Add to dashboard Cite

Many complex diseases have historically proven to be defiant to the best mono-therapeutic approaches. Several examples of combination therapies have largely overcome such challenges, notably for the treatment of severe hypertension and tuberculosis. Obesity and its consequences, such as type 2 diabetes, have proven to be equally resistant to therapeutic approaches based on single medicines. Proper management of type 2 diabetes often requires adjunctive medications, and the recent registration of a few compound mixtures has set the precedent for combinatorial treatment of obesity. On the other hand, double or triple therapeutic combinations are more difficult to advance to regulatory approval than single molecules. More recently, several classes of novel unimolecular combination therapeutics have emerged with superior efficacy than currently prescribed options and pose the potential to reverse obesity and type 2 diabetes. Here, we summarize the discovery, pre-clinical validation, and first clinical test of such peptide hormone poly-agonist drug candidates.

show abstract

Section: Get a Gip: ''Twincretins''supporting

confidence: 53%

Unimolecular Polypharmacy for Treatment of Diabetes and Obesity

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Furthermore, sulfonylureas and other long established therapeutics, including the insulin-sensitizer metformin, do not prevent the continuing loss of beta cell function observed in T2DM [91]. Incretin-based therapies are increasingly being used in clinical practice for the management of T2DM [92,93] that address a different aspect of beta cell dysfunction: the lack of potentiation of insulin secretion in response to an oral glucose/nutrient challenge [94]. This potentiation occurs because of incretins that act on the pancreas and other peripheral tissues to elicit biological effects, including augmenting nutrient-stimulated insulin secretion.…”

Section: Prevention and Therapymentioning

confidence: 99%

Obesity and diabetes: An update

Verma

Hussain

2017

Diabetes & Metabolic Syndrome: Clinical Research & Revi

238

149

View full text Add to dashboard Cite

“…For example, the influence of abdominal obesity on the risk of diabetes was found to be more important than that of general obesity [ 10 ]. Given the striking parallel increases in the incidences of these two conditions, obesity is likely an important contributing factor to the manifestation of diabetes and the complications, mortality, and morbidity related to this disease [ 11 ].…”

Section: Prevalence Of Diabetes and Obesitymentioning

confidence: 99%

Trends in the Diabetes Epidemic in Korea

Kim

2015

Endocrinol Metab

View full text Add to dashboard Cite

Diabetes mellitus is a leading cause of mortality and increased disability-adjusted life years worldwide. In Korea, the prevalence of diabetes increased from 8.6% to 11.0% in 2001 to 2013 and the prevalence of adult obesity, which is the most important risk factor of diabetes, increased from 29.2% to 31.8% during the same period. There has been a dramatic increase in the number of obese Koreans with diabetes in recent decades and the prevalence of diabetes in people aged 40 years and older also increased in 2001 to 2013. Nevertheless, the mean age at the first diagnosis of diabetes was very similar for men in 2005 and 2013, while the mean age for women decreased slightly. There is an inverse linear relationship between body mass index and age at the diagnosis of diabetes among those who are newly diagnosed. Accordingly, the prevalence of diabetes is increasingly shifting to younger individuals and those who are obese. Therefore, public efforts should focus on healthy lifestyle changes, primary prevention measures, screening for the early detection of diabetes, and long-term management.

show abstract

A new paradigm for treating obesity and diabetes mellitus

Cited by 19 publications

References 14 publications

Unimolecular Polypharmacy for Treatment of Diabetes and Obesity

Unimolecular Polypharmacy for Treatment of Diabetes and Obesity

Obesity and diabetes: An update

Trends in the Diabetes Epidemic in Korea

Contact Info

Product

Resources

About